Salidroside has been reported to exhibit anticancer properties. This study aimed to investigate the effects of salidroside on renal cell carcinoma growth. Cell viability and proliferation was assessed by Cell Counting Kit-8 and colony formation assays in A498 and 786-0 cells. The effects of salidroside on in vivo tumor growth were also assessed in a mouse xenograft model of renal cell carcinoma. Flow cytometry was used to analyze cell cycle and apoptosis and protein levels were determined by western blotting. Salidroside reduced cell viability and colony formation in both cell lines in a concentration- and time-dependent manner. Tumor growth was also suppressed in the mouse model. Furthermore, salidroside induced significant G1 phase cell cycle arrest and induced apoptosis in both A498 and 786-0 cells. Higher concentrations of salidroside reduced the levels of phosphorylated signal transducer and activator of transcription 3 (STAT3) and Janus kinase 2(JAK2). These results suggested that salidroside produced potent anticancer properties in renal cell carcinoma by modulating JAK2/STAT3 signaling. Administration of salidroside to patients with renal cell carcinoma might provide a promising therapeutic strategy for this malignancy.
ParkinD.M., BrayF., FerlayJ. and PisaniP., Global cancer statistics, 2002, CA Cancer J Clin55 (2005), 74-108.
2.
JemalA., SiegelR., WardE., MurrayT., XuJ. and ThunM.J., Cancer statistics, CA Cancer J Clin57 (2007), 43-66.
3.
HidakaH., SekiN., YoshinoH., YamasakiT., YamadaY., NohataN., FuseM., NakagawaM. and EnokidaH., Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma, Oncotarget3 (2012), 44-57.
4.
BretheauD., LechevallierE., EghazarianC., GrisoniV. and CoulangeC., Prognostic significance of incidental renal cell carcinoma, EurUrol27 (1995), 319-323.
5.
HommaY., KawabeK., KitamuraT., NishimuraY., ShinoharaM., KondoY., SaitoI., MinowadaS. and AsakageY., Increased incidental detection and reduced mortality in renal cancer-recent retrospective analysis at eight institutions, Int J Urol2 (1995), 77-80.
6.
JaysonM. and SandersH., Increased incidence of serendipitously discovered renal cell carcinoma, Urology51 (1998), 203-205.
7.
WattenbergL.W., An overview of chemoprevention: Current status and future prospects, Proc Soc Exp Biol Med216 (1997), 133-141.
8.
AmatoR.J., Chemotherapy for renal cell carcinoma, Semin Oncol27 (2000), 177-86.
9.
HungS.K., PerryR. and ErnstE., The effectiveness and efficacy of Rhodiolarosea L.: A systematic review of randomized clinical trials, Phytomedicine18 (2011), 235-44.
10.
ChenX., LiuJ., GuX. and DingF., Salidroside attenuates glutamate-induced apoptotic cell death in primary cultured hippocampal neurons of rats, Brain Res1238 (2008), 189-198.
11.
ShiT.Y., FengS.F., XingJ.H., WuY.M., LiX.Q., ZhangN., TianZ., LiuS.B. and ZhaoM.G., Neuroprotective effects of Salidroside and its analogue tyrosolgalactoside against focal cerebral ischemia in vivo and H2O2-induced neurotoxicity in vitro, Neurotox Res21 (2012), 358-267.
12.
WuT., ZhouH., JinZ., BiS., YangX., YiD. and LiuW., Cardioprotection of salidroside from ischemia/reperfusion injury by increasing N-acetylglucosamine linkage to cellular proteins, Eur J Pharmacol613 (2009), 93-99.
13.
WangH., DingY., ZhouJ., SunX. and WangS., The in vitro and in vivo antiviral effects of salidroside from Rhodiolarosea L. against coxsackievirus B3, Phytomedicine16 (2009), 146-155.
14.
LiD., FuY., ZhangW., SuG., LiuB., GuoM., LiF., LiangD., LiuZ., ZhangX., CaoY., ZhangN. and YangZ., Salidroside attenuates inflammatory responses by suppressing nuclear factor-kappaB and mitogen activated protein kinases activation in lipopolysaccharide-induced mastitis in mice, Inflamm Res62 (2013), 9-15.
15.
GuanS., HeJ., GuoW., WeiJ., LuJ. and DengX., Adjuvant effects of salidroside from Rhodiolarosea L. on the immune responses to ovalbumin in mice, Immunopharmacol Immunotoxicol33 (2011), 738-743.
16.
ZhangJ.K., YangL., MengG.L., YuanZ., FanJ., LiD., ChenJ.Z., ShiT.Y., HuH.M., WeiB.Y., LuoZ.J. and LiuJ., Protection by salidroside against bone loss via inhibition of oxidative stress and bone-resorbing mediators, PLoS One8 (2013), e57251.
17.
LiX., ErdenO., LiL., YeQ., WilsonA. and DuW., Binding to WGR domain by salidroside activates PARP1 and protects hematopoietic stem cells from oxidative stress, Antioxid Redox Signal20 (2014), 1853-1865.
18.
HuX., ZhangX., QiuS., YuD. and LinS., Salidroside induces cell-cycle arrest and apoptosis in human breast cancer cells, BiochemBiophys Res Commun398 (2010), 62-67.
19.
WangJ., LiJ.Z., LuA.X., ZhangK.F. and LiB.J., Anticancer effect of salidroside on A549 lung cancer cells through inhibition of oxidative stress and phospho-p38 expression, Oncol Lett7 (2014), 1159-1164.
20.
SunK.X., XiaH.W. and XiaR.L., Anticancer effect of salidroside on colon cancer through inhibiting JAK2/STAT3 signaling pathway, Int J Clin Exp Pathol8 (2015), 615-621.
21.
LiuZ., LiX., SimoneauA.R., JafariM. and ZiX., Rhodiolarosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of autophagy, Mol Carcinog51 (2012), 257-267.
22.
ZhangY., YaoY., WangH., GuoY., ZhangH. and ChenL., Effects of salidroside on glioma formation and growth inhibition together with improvement of tumor microenvironment, Chin J Cancer Res25 (2013), 520-526.
23.
SunC., WangZ., ZhengQ. and ZhangH., Salidroside inhibits migration and invasion of human fibrosarcoma HT1080 cells, Phytomedicine19 (2012), 355-63.
24.
Skopinska-RozewskaE., MalinowskiM., WasiutynskiA., SommerE., FurmanowaM., MazurkiewiczM. and SiwickiA.K., The influence of Rhodiolaquadrifida 50% hydro-alcoholic extract and salidroside on tumor-induced angiogenesis in mice, Pol J Vet Sci11 (2008), 97-104.
25.
LiL.L., XueA.M., LiB.X., ShenY.W., LiY.H., LuoC.L., ZhangM.C., JiangJ.Q., XuZ.D., XieJ.H. and ZhaoZ.Q., JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI, Breast Cancer Res16 (2014), R56.
26.
ChowW.H., DongL.M. and DevesaS.S., Epidemiology and risk factors for kidney cancer, Nat Rev Urol7 (2010), 245-257.
27.
CalleE.E. and KaaksR., Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms, Nat Rev Cancer4 (2004), 579-591.
28.
ChowW.H., GridleyG., FraumeniJ.F., Jr. and JarvholmB., Obesity, hypertension, and the risk of kidney cancer in men, N Engl J Med343 (2000), 1305-1311.
29.
LuscanA., ShacklefordG., Masliah-PlanchonJ., LaurendeauI., OrtonneN., VarinJ., LallemandF., LeroyK., DumaineV., HivelinM., BorderieD., De RaedtT., Valeyrie-AllanoreL., LarousserieF., TerrisB., LantieriL., VidaudM., VidaudD., WolkensteinP., ParfaitB., BiecheI., MassaadC. and PasmantE., The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesis, Clin Cancer Res20 (2014), 358-371.
30.
SherrC.J., Cancer cell cycles, Science274 (1996), 1672-1677.
31.
LiH.H., SuJ.H., ChiuC.C., LinJ.J., YangZ.Y., HwangW.I., ChenY.K., LoY.H. and WuY.J., Proteomic investigation of the sinulariolide-treated melanoma cells A375: Effects on the cell apoptosis through mitochondrial-related pathway and activation of caspase cascade, Mar Drugs11 (2013), 2625-2642.
32.
SpencerS.L. and SorgerP.K., Measuring and modeling apoptosis in single cells, Cell144 (2011), 926-939.
33.
HuX., LinS., YuD., QiuS., ZhangX. and MeiR., A preliminary study: The anti-proliferation effect of salidroside on different human cancer cell lines, Cell Biol Toxicol26 (2010), 499-507.
34.
ZhangJ., LiuA., HouR., ZhangJ., JiaX., JiangW. and ChenJ., Salidroside protects cardiomyocyte against hypoxia-induced death: A HIF-1alpha-activated and VEGF-mediated pathway, Eur J Pharmacol607 (2009), 6-14.
35.
NamS., XieJ., PerkinsA., MaY., YangF., WuJ., WangY., XuR.Z., HuangW., HorneD.A. and JoveR., Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells, Mol Oncol6 (2012), 484-493.
36.
LiuY., WangL., WuY., LvC., LiX., CaoX., YangM., FengD. and LuoZ., Pterostilbene exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2/ STAT3 signaling pathway, Toxicology304 (2013), 120-131.
37.
BillM.A., NicholasC., MaceT.A., EtterJ.P., LiC., SchwartzE.B., FuchsJ.R., YoungG.S., LinL., LinJ., HeL., PhelpsM., LiP.K. and LesinskiG.B., Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines, PLoS One7 (2012), e40724.
